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Pulmonary arterial hypertension (PAH) is characterized by dysregulated pulmonary artery endothelial cell
(PAEC) proliferation, apoptosis and permeability. Loss-of-function mutations in the bone morphogenetic pro-
tein receptor type-II (BMPR-II) are the most common cause of heritable PAH, usually resulting in haploinsuffi-
ciency. We previously showed that BMPR-II expression is regulated via a lysosomal degradative pathway.
Here, we show that the antimalarial drug, chloroquine, markedly increased cell surface expression of BMPR-II
protein independentof transcription inPAECs. Inhibitionofproteinsynthesisexperiments revealeda rapid turn-
over of cell surface BMPR-II, which was inhibited by chloroquine treatment. Chloroquine enhanced PAEC ex-
pression of BMPR-II following siRNA knockdown of the BMPR-II transcript. Using blood outgrowth
endothelial cells (BOECs), we confirmed that signalling in response to the endothelial BMPR-II ligand, BMP9,
is compromised in BOECs from patients harbouring BMPR-II mutations, and in BMPR-II mutant PAECs.
Chloroquine significantly increased gene expression of BMP9-BMPR-II signalling targets Id1, miR21 and
miR27a in both mutant BMPR-II PAECs and BOECs. These findings provide support for the restoration of cell
surface BMPR-II with agents such as chloroquine as a potential therapeutic approach for heritable PAH.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive disease
characterized by dysregulated endothelial cell proliferation,
apoptosis and vascular permeability as well as smooth muscle
cell proliferation in the pulmonary circulation (1). The trans-
forming growth factor-b (TGFb) superfamily, especially the
bone morphogenetic proteins, plays a key role in the pathobiol-
ogy of PAH (2,3). Mutations in bone morphogenetic protein
receptor type-II (BMPR-II), the gene encoding the bone morpho-
genetic protein type II receptor (BMPR-II), underlie at least
70% of heritable and 10–40% of apparently sporadic PAH
cases (4–6). In pulmonary artery smooth muscle cells, truncat-
ing or missense mutations result in reduced BMP-induced
Smad1/5 signalling and reduced transcriptional induction of
the inhibitors of DNA binding transcription factors (Id) (7,8).
The majority of mutations reported in BMPR-II lead to a state
of haploinsufficiency (6).
Endothelial cells from patients with mutations exhibit
increased proliferation and an inability to form vascular net-
works (9). Even in the absence of a BMPR-II mutation, defi-
ciency of the receptor contributes to the pathobiology of
non-genetic forms of PAH (10,11). In addition, commonly
used animal models of PAH, including chronic hypoxia in
mice or monocrotaline exposure in rats, reveal a marked reduc-
tion in BMPR-II levels in the lung (12,13). Moreover, targeted
gene delivery of BMPR-II to the pulmonary vasculature prevents
pulmonary hypertension in these models (14).
Recent studies from our laboratory have suggested the possi-
bility that lysosome inhibitors might increase cell surface
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BMPR-II levels. We previously showed that the Kaposi’s
sarcoma herpes virus E3 ligase, K5, targets BMPR-II to the lyso-
some. K5-mediated degradation could be inhibited by the select-
ive V-type ATPase inhibitor, concanamycin A. Exposure of both
pulmonary artery endothelial cells (PAECs) and smooth muscle
cells with concanamycin A resulted in a significant increase in
BMPR-II expression (15).
Originally synthesized as a treatment for malaria, chloro-
quine or the closely related compound, hydroxychloroquine,
is now widely used for the treatment of rheumatoid arthritis,
lupus erythematosus and sarcoidosis and a number of derma-
tological conditions (16–20). In addition, we have recently
shown that chloroquine prevents and reverses pulmonary
hypertension in a rat model of pulmonary hypertension char-
acterized by loss of BMPR-II expression in the lung (13,21).
Chloroquine is a lysosomotropic agent as it is usually pre-
pared as a diprotic weak base (pKa 8.5). The unprotonated
form of chloroquine preferentially accumulates in lysosomes
as it rapidly diffuses across cell/organelle membranes. Once
in the lower pH (4.6), environment of the lysosome chloro-
quine becomes protonated and can no longer freely diffuse
out (16).
In endothelial cells, BMP/TGFb signalling is mediated
through heterodimeric receptor complexes of type I and type II
receptors (22). BMP9 and BMP10 were recently identified as
specific ligands for the BMPR-II/Alk-1 receptor complex,
stimulating the activation of the receptor Smad1/5/8 pathway,
as well as downstream transcription of Id genes (23–25). Our la-
boratory recently reported that BMPR-II contributes to BMP9
stimulated induction of Smad1/5/8 phosphorylation and Id tran-
scription in PAECs (26). Since mutations in Alk-1 have also been
shown to lead to PAH, the endothelial BMPR-II/Alk-1 receptor
complex and its cognate ligands are likely to play central roles in
the pathobiology of this disease (27).
Canonical BMP signalling requires the phosphorylation of re-
ceptor Smads (R-Smads) by an activated receptor complex and
subsequent association with Smad4 for translocation into the
nucleus. It has been shown recently that non-canonical BMP sig-
nalling can directly influence the processing of microRNAs
(miRs) (28). BMPs have been shown to regulate expression of
miRs such as miR21, miR-100, miR-199a-5p and miR-27a
(28,29). Drake et al. (30) have shown that miR21, miR27a and
miR100 expression are regulated by BMP9 in PAECs, which
is dependent on intact BMPR-II.
In the present study, we determined the effects of chloroquine
on BMPR-II levels and BMP signalling in endothelial cells. We
show that chloroquine, at pharmacologically relevant concentra-
tions, rapidly increase cell surface localization of BMPR-II
protein but does not alter Alk-1 protein levels. We determined
for the first time that endogenous BMPR-II is rapidly turned
over following protein synthesis blockade, an effect that can
be inhibited by chloroquine. Chloroquine partially restored
BMPR-II expression in endothelial cells in which BMPR-II
mRNA was knocked down. Evaluation of BMP9/BMPR-II
target genes Id1, miR21 and miR27a, revealed that chloroquine
restored signalling in endothelial cells harbouring loss-of-func-
tion mutations in BMPR-II. Taken together, these findings
support a role for increasing BMPR-II expression by chloro-
quine as a potential therapeutic intervention for heritable PAH.
RESULTS
Chloroquine increases BMPR-II protein levels
in endothelial cells
We sought to investigate whether lysosome blockade by chloro-
quine could significantly increase BMPR-II levels in endothelial
cells. Treatment of PAECs for 16 h with either concanamycin A
(50 nM) or chloroquine (100 mM) significantly increased
BMPR-II protein levels by 5.6- and 3.5-fold, respectively
(Fig. 1A). Transcription of BMPR-II mRNA was not significant-
ly elevated suggesting that the increase in BMPR-II was likely
due to lysosomal pathway inhibition (Fig. 1B). We also sought
to determine whether the targeting of BMPR-II for lysosomal
degradation by K5 mediated ubiquitination could be inhibited
by chloroquine (15). Although not as marked as concanamycin
A, chloroquine treatment of HeLa cells stably expressing K5 par-
tially restored BMPR-II protein levels (Fig. 1C). Furthermore, in
a microvascular endothelial cell line BMPR-II expression levels
were strikingly increased by chloroquine (Fig. 1C). Again,
chloroquine had no effect on BMPR-II gene expression in any
of the cell lines (Fig. 1D).
Plasma levels of chloroquine in patients treated for rheumatoid
arthritis vary from 36.6 to 3895 ng/ml (18). We conducted a con-
centration response assay encompassing this range. PAECs were
treated for 16 h with the following concentrations 0, 0.5, 1, 5, 10
and 50 mM. Treatment with 0.5–50 mM chloroquine, increased
BMPR-II protein expression in a dose response manner, com-
pared with the no treatment control (Fig. 2A and Supplementary
Material, Fig. S1). Even at the higher concentrations of chloro-
quine, expression of the endothelial specific type I receptor,
Alk-1, was not significantly affected (Fig. 2A, grey bars).
Chloroquine increases cell surface localization of BMPR-II
We next sought to investigate whether lysosomal inhibition
affected BMPR-II cell surface localization. A MCR5 lung fibro-
blast cell line stably expressing GFP-tagged BMPR-II was cul-
tured in glass chamber slides and treated with the relevant
vehicle, concanamycin A (50 nM) or chloroquine (100 mM) for
16 h. Using confocal microscopy, GFP-tagged BMPR-II was
localized at the cell surface in the vehicle control (Fig. 2C–F).
After treatment with concanamycin A, the GFP-tagged receptor
co-localized with the lysosomal marker, LAMP-1 (Fig. 2G–J).
Under these conditions, very little receptor was observed at the
cell surface suggesting rapid turnover of the receptor and accu-
mulation in the lysosome. Treatment with chloroquine also
resulted in lysosomal accumulation, but also appeared to in-
crease GFP-tagged BMPR-II at the cell surface (Fig. 2K–N;
arrowheads).
To determine BMPR-II cell surface localization, biotinylation
of cell surface receptors was utilized. Cells were treated for 16 h
with vehicle, concanamycin A (50 nM) and chloroquine
(100 mM). The non-biotinylation control showed basal expres-
sion of BMPR-II in the total lysate, but no surface expression
with the avidin-agarose beads alone. Both concanamycin A
and chloroquine increased total cell lysate BMPR-II expression
compared with the vehicle control, but only chloroquine
appeared to increase surface expression of BMPR-II (Fig. 3A).
Biotinylation was also utilized to determine surface expression
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of endogenous BMPR-II in PAECs after a chloroquine concen-
tration response. Biotinylation analysis revealed that all chloro-
quine concentrations (0.5–50 mM) increased surface expression
of BMPR-II (Fig. 3B; arrowhead). Therefore, a concentration of
10 mM chloroquine, which reflects high steady-state blood con-
centrations in patients, was chosen for further experiments.
We next sought to determine the time course of chloroquine
action on BMPR-II expression. PAECs were treated with chloro-
quine at 10 mM for 0.5, 1, 2, 4 and 16 h. BMPR-II protein levels
were increased after 2–4 h chloroquine treatment (Fig. 3C). No
significant increases in BMPR-II mRNA levels were observed at
these time points (Fig. 3D).
Figure 1. Inhibition of the lysosome by concanamycin A and chloroquine significantly increases endogenous expression of BMPR-II in endothelial cells. (A) Human
PAECs were treated for 16 h with DMSO (vehicle), concanamycin A (50 nM) or chloroquine (100 mM). Total BMPR-II expression was assessed by immunoblotting
and reprobed fora-tubulin to ensure equal loading. Immunoblots of BMPR-II expression were quantified and expression represented as the ratio of BMPR-II:loading
control. Bar graph showing BMPR-II fold change after lysosomal inhibition relative to appropriate vehicle control. ∗P , 0.05 compared with control (n ¼ 3).
(B) Total RNA was extracted and cDNA was prepared from treated PAECs. BMPR-II gene expression was determined by qPCR. Expression was normalized to
B2M and represented as a fold change relative to control. (C) HeLa cells, HeLa-K5 and HMEC-1 cell lines were treated for 16 h with vehicle (DMSO), concanamycin
A (50 nM) and chloroquine (100 mM). BMPR-II expression was assessed by immunoblotting and reprobed for a-tubulin to ensure equal loading. (D) Total RNA was
extractedand cDNA was prepared from treated cell lines. BMPR-II gene expressionwas determined by qPCR. Expression was normalized to B2M and represented as a
fold change relative to control (HeLa + vehicle).
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Chloroquine inhibits the degradation of cell surface
BMPR-II
In order to determine the effects of chloroquine on BMPR-II ex-
pression, the understanding of turnover of endogenous receptor
is critical. The dynamics of BMPR-II regulation were
investigated by blocking protein synthesis with cycloheximide
over a time course. PAECs were treated with 20 mg/ml cyclo-
heximide at 0, 0.5, 1, 2 and 4 h and assessed for BMPR-II
protein and gene expression. Loss of total receptor expression
was observed as early as 1 h (Fig. 4A). BMPR-II gene expression
was unaffected across the time course (Fig. 4B; white bars).
Figure2.Chloroquine increases expression of BMPR-II at physiologically relevant concentrations and surface expression in lung fibroblasts. (A) HumanPAECs were
treated for 16 h with the following concentrations of chloroquine 0.5, 1, 5, 10 and 50 mM. Total BMPR-II expression was assessed by immunoblotting and reprobed for
a-tubulin to ensure equal loading. (B) Total RNA was extracted and cDNA was prepared from treated PAECs. BMPR-II and Alk-1 gene expression was determined by
qPCR. Expression was normalized to B2M and represented as a fold change relative to control. (C–N) MRC5-BMPR-II-GFP cells were treated for 16 h with DMSO
(vehicle), concanamycin A (50 nM) or chloroquine (100 mM) and assessed by confocal microscopy. Cells were immunostained for the lysosomal marker, LAMP-1 and
counterstained with DAPI.
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Blockade of protein synthesis had no effect on Alk-1 protein and
gene expression (Fig. 4A and B; grey bars).
To determine whether chloroquine alters the loss of BMPR-II
following protein synthesis inhibition, PAECs were pre-treated
with chloroquine (10 mM) for 16 h prior to cycloheximide treat-
ment. As observed previously, BMPR-II expression was lost
rapidly after 1 h, but treatment with chloroquine preserved ex-
pression after 2 h (Fig. 4C). Again no significant effect on
BMPR-II gene expression was observed (Fig. 4D). Rapid loss
of BMPR-II was also seen in PASMCs after 1–2 h (Supplemen-
tary Material, Fig. S2). Furthermore, 16 h chloroquine treatment
of PASMCs maintained BMPR-II expression over 2–4 h of
protein synthesis blockade.
Since the pre-treatment with chloroquine for 16 h inevitably
increased BMPR-II expression, we also conducted experiments
in which the level of BMPR-II protein was similar to time 0 by
pre-treating PAECs for only 1 h with chloroquine (10 mM)
(Fig. 5A). Normalization of chloroquine-treated BMPR-II
Figure 3. Chloroquine increases cell surface expression of BMPR-II at physio-
logically relevant concentrations. (A) Treated MRC5-BMPR-II-GFP cells
were surface protein biotinylated and assessed for BMPR-II expression in the
biotinylation pulldown and total cell lysate by immunoblotting. (B) Human
PAECs were treated for 16 h with chloroquine at 0.5, 1, 5, 10 and 50 mM.
Surface proteins were biotinylated and BMPR-II expression was assessed in
the biotinylated fraction and total cell lysate by immunoblotting. (C) Human
PAECs were treated with chloroquine (10 mM) for 0, 0.5, 1, 2, 4 and 16 h.
Total BMPR-II expression was assessed by immunoblotting and reprobed for
a-tubulin to ensure equal loading. (D) Human PAECs were treated with chloro-
quine (10 mM) for 0, 0.5, 1, 2, 4 and 16 h. Total RNA was extracted and cDNA was
prepared from treated cell lines. BMPR-II gene expression was determined by
qPCR. Expression was normalized to B2M/b-actin and represented as a fold
change relative to control (0 h).
Figure 4.Rapid turnover of BMPR-II can be inhibited by chloroquine treatment.
(A) Protein synthesis in human PAECs was inhibited by cycloheximide treatment
(20 mg/ml). Protein expression was assessed after protein synthesis blockade
over a time course of 0, 0.5, 1, 2, 4 h. Total BMPR-II and Alk-1 expression
were assessed by immunoblotting and reprobed for a-tubulin to ensure equal
loading. (B) Total RNA was extracted and cDNA was prepared from treated
PAECs. BMPR-II and Alk-1 gene expression were determined by qPCR. Expres-
sion was normalized to B2M and represented as a fold change relative to control.
(C) Human PAECs were treated for 16 h with chloroquine (10 mM) prior to
protein synthesis inhibition. BMPR-II expression was assessed by immunoblot-
ting and reprobed for a-tubulin to ensure equal loading. (D) Total RNA was
extracted from treated PAECS and cDNA prepared. BMPR-II gene expression,
determined by qPCR, was normalized to B2M and represented as a fold
change relative to control.
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expression prior to protein synthesis inhibition revealed that
chloroquine increased and maintained BMPR-II expression sig-
nificantly until 2 h (Fig. 5B).
Chloroquine restores BMPR-II protein levels following
siRNA knockdown
Both genetic and non-genetic forms of PAH are often character-
ized by reduced BMPR-II protein expression (10). We therefore
sought to recreate the diminished receptor expression seen in the
disease using RNA interference. In our previous research, silen-
cing of BMPR-II with 10 nM siRNA results in over 90% knock-
down efficiency (26). Therefore, serial dilutions of siRNA were
used to recreate the ‘haploinsufficient’ levels of BMPR-II
protein expression. PAECs were transfected with 10, 1, 0.1
and 0.01 nM of BMPR-II. After 48 h, protein and transcript
levels were assessed for knockdown efficiency. A concentration
of 0.1 nM siRNA decreased BMPR-II protein (Fig. 6A) and
mRNA (Fig. 6B) expression levels by 50% compared with
the transfection control. To allow for variability between
PAEC donors, concentrations of 0.1 and 1 nM siRNA were
used in subsequent experiments to determine whether chloro-
quine can rescue BMPR-II protein expression. Knockdown of
BMPR-II was conducted as before except that after 32 h cells
were treated with chloroquine for 16 h. BMPR-II expression
was reduced to 50% levels in the siBMPR-II knockdown at a
concentration of 1 nM. Densitometry of three independent
experiments revealed that chloroquine treatment increased
BMPR-II levels by 2.2- and 6.5-fold following knockdown
with 0.1 and 1 nM of siRNA, respectively (Fig. 6C).
Figure 5.Chloroquine significantly maintains BMPR-II expression after protein
synthesis inhibition. (A) Human PAECs were treated with chloroquine (10 mM)
for 1 h prior to protein synthesis inhibition. BMPR-II expression was assessed by
immunoblotting and blots were reprobed for a-tubulin to ensure equal loading.
(B) Immunoblots of BMPR-II expression were quantified and expression repre-
sented as the ratio of BMPR-II:loading control. BMPR-II expressionwas normal-
ized to vehicle time 0 (n ¼ 3). ∗P, 0.05 compared with control.
Figure6.Chloroquine increases BMPR-II protein expression in endothelial cells
expressing50% less BMPR-II gene expression. (A) Human PAECs were trans-
fected with siBMPR-II or siCP at 0.01, 0.1, 1 or 10 nM using Dharmafect1 (DH).
Total BMPR-II protein expression was assessed using immunoblotting. Blots
were reprobed for a-tubulin to ensure equal loading. (B) Total RNA and
cDNA were prepared. BMPR-II expression was determined by qPCR with ex-
pression normalized to B2M and expressed as the fold change relative to
DH-transfected cells. (C) Human PAECs were transfected with siBMPR-II or
siCP at 0.1 or 1 nM using Dharmafect1 (DH). After 32 h, cells were treated for
16 h with chloroquine (10 mM). BMPR-II protein expression was assessed
using immunoblotting. Blots were reprobed for a-tubulin to ensure equal
loading. Data are from three experiments.
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Chloroquine does not inhibit BMP-mediated Smad
signalling and transcription of target genes
Since chloroquine inhibits the internalization of BMPR-II, it is
possible that signalling downstream of the receptor could be ad-
versely affected by this intervention. In addition, off-target
effects of chloroquine might negatively impact BMP signalling.
To assess this, PAECs were stimulated with BMP9 (1 ng/ml) in
the presence of chloroquine (10 mM). Downstream signalling
was assessed by examining canonical Smad1/5/8 protein phos-
phorylation and Id1 transcription. Cells were pre-treated with
chloroquine for 16 h prior to stimulation with BMP9 for 1 and
4 h. As previously observed, BMP9 stimulation increased
BMPR-II protein and gene expression (26) (Fig. 7A and B). As
previously described in this study, chloroquine substantially
increased BMPR-II protein expression, but not mRNA
(Fig. 7A and B). Phosphorylation of Smad1/5/8 was increased
by BMP9 treatment at both 1 and 4 h, which was unaffected by
chloroquine (Fig. 7A). BMP9 potently increased Id1 gene ex-
pression particularly after 1 h stimulation (Fig. 7C). Again,
this was unaffected by chloroquine treatment suggesting no det-
rimental effect of blocking the lysosome on BMP signalling in
endothelial cells. In fact, Smad1/5/8 phosphorylation and Id1 ex-
pression remained unaffected by chloroquine for up to 8 h of
BMP9 exposure (Supplementary Material, Fig. S3A–C).
Furthermore, no discernible increase in Smad-independent sig-
nalling was observed when examining p38MAPK phosphoryl-
ation after BMP9 treatment in the presence of chloroquine
(Supplementary Material, Fig. S4).
Chloroquine increases BMPR-II protein expression and
improves downstream signalling in endothelial cells
harbouring BMPR-II mutations
Initially, we confirmed that endothelial cells derived from
patients with BMPR-II mutations are deficient in BMP9-
mediated signalling. After quiescence, control and BMPR-II
haploinsufficient blood outgrowth endothelial cells (BOECs)
were treated with BMP9 (1 ng/ml) for 4 and 12 h. After 12 h,
mutant BOECs showed a significantly reduced Id1 expression
compared with controls (Fig. 8A). Furthermore, Id1 expression
in a haploinsufficient BMPR-II PAECs, after 20 h BMP9 stimu-
lation, was also significantly reduced (Fig. 8B).
Drake et al. (30) recently observed that miR21 and miR27a ex-
pression are regulated by BMP9. In that study, BMP9-stimulated
miR21 and miR27a levels were completely abrogated by RNA
interference of BMPR-II. We therefore assessed the effect of
chloroquine on the processing of these microRNAs and Id1
gene expression. Control and BMPR-II haploinsufficient
PAECs were pre-treated with chloroquine for 4/16 h prior to
stimulation with BMP9 for 20 h. BMP9 stimulation of control
PAECs induced miR21 and miR27a expression (Fig. 8B). As
expected, haploinsufficient PAECs showed very little induction
of these targets in the presence of BMP9. Chloroquine exerted no
effect on the processing of miR21 and miR27a in the control cells
after 16 h chloroquine pre-treatment. PAECs from a PAH patient
with a BMPR-II mutation (deletion of exons 1–8) showed a sig-
nificant reduction in BMP9 stimulated miR21, mir27a and Id1
levels (Fig. 8C). Chloroquine treatment of haploinsufficient
PAECs significantly increased the expression of Id1, miR21
and miR27a in the presence of BMP9 (Fig. 8C). Similar signifi-
cant results were observed after 4 h chloroquine pre-treatment
and subsequent exposure to BMP9 (Supplementary Material,
Fig. S5).
Control and mutant PAECs were pre-treated with chloroquine
for 4 and 16 h and BMPR-II protein expression was measured.
Figure 7. Canonical Smad signalling after BMP9 treatment is unaffected by
chloroquine treatment. (A) HumanPAECs were treated for 16 h with chloroquine
(10 mM) or vehicle in growth factor restricted conditions. Cells were treated with
BMP9 (1 ng/ml) for 1 or 4 h. Immunoblotting was performed with antibodies
against BMPR-II, phospho-Smad1/5/8 or total Smad1. Blots were reprobed
with a-tubulin to ensure equal loading. (B and C) Human PAECs were treated
for 16 h with chloroquine (10 mM) or vehicle in growth factor restricted condi-
tions. Cells were treated with BMP9 (1 ng/ml) for 1 or 4 h. Total RNA was
extracted and cDNA prepared. Expression of BMPR-II (B) and Id1 (C) were
determined by qPCR. Expression was normalized to B2M and expressed as
fold change relative to control (EBM-2/2% FBS). ∗∗∗P, 0.001 compared
with control. Data are mean+ SEM (n ¼ 3).
Human Molecular Genetics, 2013, Vol. 22, No. 18 3673
An increase in BMPR-II levels was observed in control cells
after 4 and 16 h chloroquine treatment (Fig. 8D). Significantly,
an increase in BMPR-II protein expression in haploinsufficient
PAECs was observed in cells treated for 4 and 16 h with chloro-
quine (Fig. 8D). We further assessed the effect of chloroquine on
BOECs from two patients with a BMPR-II mutation (R320X and
R548X). Chloroquine treatment significantly increased total
BMPR-II expression after 4 and 16 h in mutant BOECs
(Fig. 9A and Supplementary Material, Fig. S6). Densitometry
from the mutant PAEC line and haploinsufficient BOEC lines
confirmed a significant increase in BMPR-II expression in the
presence of chloroquine (Fig. 9B). The BMPR-II mutant
R320X BOECs demonstrated significantly lower Id1 expression
compared with controls after 20 h of BMP9 stimulation
(Fig. 7C). Furthermore, 16 h chloroquine pre-treatment signifi-
cantly increased Id1 expression in the presence of BMP9
(Fig. 9C).
DISCUSSION
The type II bone morphogenetic protein receptor plays a critical
role in PAH. In those cases where a mutation is identified,
reduced expression of BMPR-II is observed in the lung. Further-
more, idiopathic cases of the disease in the absence of BMPR-II
mutation, and animal models of disease are all associated with a
marked reduction in lung BMPR-II protein levels (10–13).
Therefore, the ability to maintain the cell surface expression of
BMPR-II is of particular interest in the treatment of PAH.
Our recent study highlighted the potential in targeting the
regulation of BMPR-II by inhibiting the lysosome (15). We
have also recently reported that treatment of monocrotaline
exposed rats with chloroquine not only inhibited the develop-
ment of PAH in this model but also increased lung BMPR-II
protein levels consistent with our observation that lysosome
blockade increases endogenous expression of the receptor
Figure 8. Reduced Id1, miR21 and miR27a expression in BMPR-II mutant cells is restored by chloroquine treatment. (A) Human blood outgrowth endothelial cells
(BOECs) were quiesced in 0.1% serum overnight and then treated with BMP9 (1 ng/ml) for 4 and 12 h. Expression of Id1 was determined by qPCR and normalized to
b-actin. ∗P , 0.05 compared with control PAECs treated with BMP9 for 12 h. Data are mean+SEM (n ¼ 3/4). (B) Human PAECs were treated with BMP9 (3 nM)
for 20 h prior to total RNA extraction. Expression of Id1, miR21 and miR27a were determined by qPCR. miR21 and miR27a expression were normalized to RNU48
and Id1 expression was normalized to GAPDH. (C) Human PAECs were pre-treated with chloroquine (10 mM) for 16 h prior to BMP9 stimulation for 20 h. Total RNA
was extracted and expression of miR21, miR27a and Id1 determined as above. All quantitative PCR assays were performed in triplicate for each of the three inde-
pendent RNA preparations. Fold-change was calculated as the quotient of transcript in BMP9- over vehicle-treated cells for each condition. ∗∗∗P , 0.001 compared
with relevant control. Data are mean+ SEM (n ¼ 9). (D) Human PAECs were treated with chloroquine (10 mM) or vehicle for 4 or 16 h. Immunoblotting was per-
formed with a BMPR-II antibody and blots were reprobed with a-tubulin to ensure equal loading. Different exposure times were required due to the lower BMPR-II
levels in the mutant PAECs.
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(21). The potential mechanisms involved in the regulation of
BMPR-II expression levels remain poorly understood.
Here, we report that chloroquine was able to partially restore
K5 mediated ubiquitination and downregulation of BMPR-II in
HeLa cells, similar to our previous findings with concanamycin
A (15). Although both inhibitors block the lysosomal degrada-
tive pathway by affecting lysosomal acidification, their effect
on BMPR-II localization differed. Concanamycin A is a select-
ive inhibitor of vacuolar ATPases. Vacuolar ATPases are proton
pumps localized to the membranes of many intracellular
organelles and primarily regulate intracellular pH (31). Inhib-
ition by concanamycin A immediately increases luminal pH
(32). It is worth noting that bafilomycin A1, another macrolide
antibiotic, has been shown to completely abolish EGF lysosomal
degradation but had no affect on ligand internalization and endo-
cytosis (33). The high toxicity of concanamycin A and other
macrolides precludes their use in clinical therapy. The mode of
action of chloroquine is as a weak lipophilic base where the
free base passes easily through membranes (34). It accumulates
in the acidic lysosome as it becomes protonated, increasing the
pH of the lysosome (35,36). Following exposure to concanamy-
cin A, BMPR-II accumulates in the lysosome, but with chloro-
quine treatment BMPR-II appeared to be increased at the
plasma membrane in addition to a degree of lysosomal accumu-
lation. Since BMPR-II is known to be degraded via the lysosome
(15), we speculate that inhibition of lysosomal degradation of
BMPR-II leads to the accumulation of the protein within this or-
ganelle, as was observed in our confocal imaging studies. Mas-
sague´ and Kelly (37) reported that upon TGFb binding the
ligand:receptor complex is rapidly internalized for lysosomal
degradation and is blocked by chloroquine treatment. Further-
more, they postulated that TGFb receptors are replenished by re-
cycling of a large intracellular pool. Therefore, one of the
possible therapeutic benefits of chloroquine could be in main-
taining BMPR-II at the cell surface. Given the current lack of
antibodies directed at the extracellular domain to assess cell
surface expression of BMPR-II, we employed an alternative
method. In order to measure increased cell surface expression
of BMPR-II in the presence of chloroquine, biotin labelling of
cell surface molecules was utilized.
In this study, we sought to characterize the effect of chloro-
quine on BMPR-II levels in the endothelium. Recent research
using PAECs from a persistent pulmonary hypertension model
in fetal lambs described impaired angiogenesis which could be
rescued by chloroquine inhibition of autophagy (38).
However, as yet there is no literature describing the regulation
of BMPR-II by chloroquine in endothelial cells. The most strik-
ing observation from this study was the apparent ability of
chloroquine to maintain surface expression of BMPR-II, espe-
cially at pharmacologically relevant concentrations. The in-
crease in BMPR-II protein expression was not dependent on
increased BMPR-II transcription. We also found that BMPR-II
protein levels are rapidly reduced after protein synthesis inhib-
ition. In contrast, the protein expression of the endothelial specif-
ic type I receptor, Alk-1, was unaffected. Hartung et al. (39) have
previously reported that type I and II BMP receptors undergo
constitutive endocytosis. These studies were conducted in
fibroblast-like COS7 and mouse myoblast C2C12 cell lines.
Nevertheless, these observations support our findings that
BMPR-II expression is rapidly lost after protein synthesis block-
ade. The rapid loss of BMPR-II could be partially inhibited by
chloroquine.
The ability to rescue reduced receptor expression could be a
critical factor in the treatment of PAH. The majority of heritable
or idiopathic PAH cases, where a mutation in BMPR-II is iden-
tified, are due to nonsense, frameshift and splice-site defects.
This results in the premature termination of BMPR-II transcript
and therefore loss of expression through nonsense-mediated
decay (40). Haploinsufficiency for BMPR-II with a 50% reduc-
tion in BMPR-II expression is predicted in these individuals. We
Figure 9. Chloroquine treatment significantly increases BMPR-II protein ex-
pression and rescues Id1 gene expression in mutant BOECs. (A) Human
BOECs were treated with chloroquine (10 mM) or vehicle for 4 or 16 h. Immuno-
blotting was performed with a BMPR-II antibody and blots were reprobed with
a-tubulin to ensure equal loading. (B) Immunoblots of BMPR-II expression
were quantified and expression represented as the ratio of BMPR-II:loading
control. Bar graph showing BMPR-II fold change after chloroquine treatment
relative to control (n ¼ 3). ∗P , 0.05 compared with control. (C) Human
BOECs were pretreated with chloroquine (10 mM) for 16 h prior to BMP9
(3 nM) stimulation for 20 h. Total RNA was extracted and expression of Id1 deter-
mined by qPCR. Expression was normalized to b-actin and expressed as fold
change relative to control. ∗P, 0.05 and ∗∗P, 0.01 compared with control.
Data are mean+ SEM (n ¼ 3).
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attempted to recreate this expression level by titration of the
BMPR-II siRNA previously used (26). Using 10–100-fold dilu-
tions of siRNA, we were able to mimic the reduction in expres-
sion levels associated with BMPR-II mutations (10). Treatment
with chloroquine partially restored the receptor expression
levels where BMPR-II levels were 50% or lower. More import-
antly, chloroquine treatment of endothelial cells from patients
with BMPR-II mutations partially rescued BMPR-II protein
expression.
Preventing the cell surface turnover of BMPR-II might impair
BMP signalling. We determined the effect of chloroquine on
BMP9 induced Smad signalling and its downstream transcrip-
tion factor, Id1. In control PAECs, chloroquine was not detri-
mental to the canonical signalling processes mediated by
BMP9. As previously reported by Drake et al. (30), we con-
firmed that PAECs and BOECs harbouring a BMPR-II mutation
are deficient in the induction of Id1 expression and processing of
microRNAs, miR21 and miR27a by BMP9. This contrasts with
our previous report in which we employed siRNA knockdown of
BMPR-II and ActR-IIa to show that induction of Id gene expres-
sion by BMP9 in PAECs was co-dependent on these receptors
(26). This highlights important differences between the experi-
mental knockdown of a receptor and study of the endogenous
mutated receptor. Nevertheless, in cells harbouring BMPR-II
mutations in the present study, we demonstrate that chloroquine
treatment of BMPR-II mutant endothelial cells can rescue the ex-
pression of these downstream BMP9/BMPR-II targets. Our
results suggest that enhancement of cell surface expression of
BMPR-II in the normal endothelium does not further increase
signalling in response to ligand, rather our findings suggest
that BMPR-II limits BMP signalling at lower levels of receptor
expression. Under these circumstances, in the presence of
BMPR-II haploinsufficiency, chloroquine was capable of en-
hancing BMP signalling. This gene dosage effect of BMPR-II
has been reported previously in vivo (41). At present, it
remains uncertain whether the optimal point for intervention
on the mutated BMPR-II pathway is at the level of the receptor
itself, or the downstream signalling. Thus in a situation where
BMP signalling was deficient downstream of the receptor,
enhanced BMPR-II expression levels may be ineffective. Never-
theless, in in vivo rat models of pulmonary hypertension where
several mechanisms likely mediate loss of BMP signalling, we
have shown that chloroquine can prevent onset and progression
of disease (21).
This study is the first report of the dynamic regulation of
BMPR-II and the possibility to modulate cell surface expression
with a widely used therapeutic agent. However, several questions
remain regarding the mechanism of BMPR-II degradation and
turnover in the endothelium, in addition to the potential
non-specific effects of chloroquine. It is well known that 4-
aminoquinolones have a wide range of effects. Other than modi-
fying lysosomal acidification, they have been shown to target
other molecules involved in endocytic degradation. Accumula-
tion of chloroquine in the lysosome inhibits phospholipase A2
(16). It has recently been shown that antagonists of cytoplasmic
phospholipase A2 inhibit multiple endocytic pathways (42). In
this case, chloroquine could be maintaining BMPR-II at the cell
surface via another mechanism other than lysosomal inhibition.
There have been several reports detailing the endocytic path-
ways involved in TGFb superfamily receptor degradation. In
particular, Hartung et al. (39) established roles for both clathrin
and caveolae mediated endocytosis in the processing of
BMPR-II. Furthermore, they identified that BMPR-II interacts
with Eps15R, a key component of clathrin coated pits (CCPs),
and caveolin-1, the main component of caveolae. BMPR-II
has also been shown, using fluorescence resonance energy trans-
fer, to bind another key component of CCPs, adaptor protein
complex 2 (AP2). Disruption of CCPs increased Smad signalling
and osteogenesis in C2C12s, suggesting that CCPs operate as an
inhibitory membrane domain (43).
Recent research has highlighted the importance of caveolin-1
in vascular signalling and pulmonary hypertension. BMPR-II
has been reported to localize in lipid rich membrane domains
of PAECs and co-localize with caveolin-1 (44). Caveolin-1
has also been shown to be important in vascular smooth
muscle cell signalling. Targeted reduction of caveolin-1 using
RNA interference resulted in reduced BMP signalling (45). Fur-
thermore, caveolin-1 knockout mice develop right ventricular
hypertrophy and an increase in pulmonary artery pressure (46).
Mutations in several members of the BMP/Smad signalling
cascade have been identified in PAH patients, including Alk-1,
endoglin and Smad8. Recently, Austin et al. (47) were the first
to identify a frameshift mutation in caveolin-1 in a family with
heritable PAH and an individual with idiopathic PAH. Thus,
providing a link between the regulation of BMP signalling and
endocytosis in pulmonary hypertension. Despite these consid-
erations, chloroquine and hydroxychloroquine are widely used
in clinical practise and would appear on the basis of our
present and recent findings to be worth pursuing in clinical
studies as potentiators of BMP signalling in PAH, where BMP
signalling is compromised (21).
Taken together, our findings provide proof of concept for tar-
geting the degradation of the BMPR-II receptor in PAH asso-
ciated with BMPR-II deficiency or mutation to restore
downstream signalling and function. Further elucidation of the
mechanisms by which BMPR-II is degraded from the cell
surface via the lysosome may provide additional specific
targets for intervention.
MATERIALS ANDMETHODS
Cell culture
Human PAECs were purchased from Lonza, Workingham, UK.
Cells were maintained in complete endothelial cell growth
medium-2 (EGM-2) and were used at passages 4–8. PAECs
from a PAH patient with a germline mutation in BMPR-II (dele-
tion of exons 1–8) were isolated as previously described
(30,48,49). BOECs were isolated as previously described (9).
Cells were maintained in complete EGM-2 and were used at pas-
sages 5–7. The transformed human microvascular endothelial
cell line (HMEC-1) was obtained from the Centre for Disease
Control (CDC, Atlanta, Georgia, USA) and maintained in the
MDCB131 medium (Life Technologies, Paisley, UK) contain-
ing 15% fetal bovine serum (FBS) (Life Technologies), 10 ng/
ml EGF, 1 ng/ml hydrocortisone (Sigma-Aldrich, Poole,
Dorset, UK) and antibiotics. Human pulmonary artery smooth
muscle cells (PASMCs) were isolated in our laboratory by
explants and cultured as previously described (50). Immorta-
lized MRC5 (SV40T) lung fibroblasts stably expressing
3676 Human Molecular Genetics, 2013, Vol. 22, No. 18
human wild-type BMPR-II-GFP (MRC5-BMPR-II-GFP) were
cultured as previously described (51). HeLa cell lines were
grown in DMEM supplemented with 10% FBS and antibiotics.
The HeLa K5 stable cell line was created and cultured as previ-
ously described (15). Concanamycin A was dissolved in DMSO
and used at a final concentration of 50 nM for 16 h. Chloroquine
(N4-(7-Chloro-4-quinolinyl)-N1,N1-dimethyl-1,4-pentanedia-
mine diphosphate salt) was dissolved in sterile nuclease-free
water and used at differing concentrations and times (both
Sigma-Aldrich). Cycloheximide was dissolved in sterile
nuclease-free water and used at 20 mg/ml (Sigma-Aldrich).
For BMP9 treatments, see relevant figure legends.
mRNA quantitative reverse transcriptase-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen,
Crawley, UK) according to the manufacturer’s protocol along
with on-column DNase digestion. Total RNA (1000 ng) was
reverse transcribed using the high capacity reverse transcription
kit (Applied Biosystems, Warrington, UK) as described in the
manufacturer’s instructions. Synthesized complementary DNA
was amplified using SYBRw-Green JumpStartTM Taq Ready-
MixTM (Sigma-Aldrich) and the relevant sense and antisense
primers along with ROX Reference dye (Life Technologies).
The following primer sequences were used for BMPR-II (sense
5′-caaatctgtgagcccaacagtcaa-3′, anti-sense 5′-gaggaagaataatctgg
ataaggaccaat-3′); b-actin (sense 5′- gcaccacaccttctacaatga-3′,
antisense 5′-gtcatcttctcgcggttggc-3′). QuantiTect Primer Assays
were used for Alk-1, ID1, GAPDH and b2-microglobulin
(B2M) (Qiagen). Reactions were amplified on a StepOnePlusTM
Real-Time PCR System (Applied Biosystems). Relative expres-
sion of target mRNA was normalized to GAPDH, b-actin or
B2M using the DDCT method (52) and expressed as fold
change relative to the relevant control.
microRNA quantitative reverse transcriptase-PCR
Total RNA was extracted using miRNeasy mini kit (Qiagen,
Valencia, CA, USA). miR21 and miR27a were quantified
using TaqMan microRNA kits (Applied Biosystems, Foster
City, CA, USA) and normalized to RNU48 as previously
described (30).
RNA interference
PAECs were seeded in 60 mm dishes (4.38 × 105 cells/well) for
protein or six-well plates (2 × 105 cells/well) for RNA and cul-
tured for 48 h in EGM-2. Before transfection, PAECs were incu-
bated in Opti-MEM I (Life Technologies) for 3–4 h. PAECs
were transfected with 0.01, 0.1, 1 or 10 nM siRNA (BMPR-II
(Dharmacon siGENOME SMARTpool) or siControl non-
targeting (both Dharmacon On-TARGETplus) (Perbio
Science, Erembodegem-Aalst, Belgium) complexed with Dhar-
maFECT1 (8.75 ml/well for 60 mm dish or 4 ml/well for six-well
plate) diluted in Opti-MEM I. Cells were incubated with the siR-
NA:DharmaFECT1 complexes for 4 h at 378C, and then
replaced with EGM-2. Knockdown efficiency was confirmed
by qPCR and western blotting where possible.
Western blotting
Cells were grown to confluence in 60 mm dishes prior to the rele-
vant treatment as detailed in the results section. Cells were lysed
in 150 ml of ice cold lysis buffer (50 mM Tris–HCl, pH 8;
150 mM NaCl; 1% IGEPAL CA-630; 0.5% deoxycholate;
0.1% SDS and 1x EDTA-free protease inhibitor cocktail)
(Roche, West Sussex, UK) and centrifuged for 10 min at 10
000g. Protein concentration was determined using the Bio-Rad
Lowry assay (Bio-Rad Laboratories, Hemel Hempstead, UK),
using bovine serum albumin (BSA) as the standard. An equal
amount of protein from each sample was diluted with 5×
sample loading buffer and boiled for 5 min. Cell lysates (40–
80 mg of total protein) were separated by SDS–PAGE gels
and proteins transferred to polyvinylidene fluoride membranes
by semi-dry blotting. Blots were blocked and probed with the
relevant antibodies. BMPR-II mouse monoclonal (BD Trans-
duction Laboratories, NJ, USA); GFP mouse monoclonal
(Roche); phospho-Smad1/5/8 rabbit polyclonal, total Smad1
rabbit polyclonal, phospho-p38MAPK and total p38MAPK
(Cell Signaling Technology, Danvers, MA, USA). The Alk-1
rabbit polyclonal was a kind gift from Professor D Marchuk
(Duke University, NC, USA). Blots were incubated with an ap-
propriate horseradish-peroxidase-conjugated antibody and
enhanced chemiluminescence reagent (GE Bioscience, Little
Chalfont, UK). To confirm equal loading blots were incubated
with an anti-a-tubulin antibody (Sigma-Aldrich).
Cell surface biotinylation
Method adapted from Rennolds et al. (53). PAECs or
MRC5-BMPR-II-GFP cells were seeded in 60 mm dishes
(4.38 × 105 or 7 × 105 cells/well, respectively) and cultured
for 48 h prior to treatment. Cells were treated as described in
the relevant results section. After treatment cells were placed
on ice and washed twice with ice-cold PBS. Cells were washed
once with PBS pH 8 containing 1 mM MgCl2 and 0.1 mM
CaCl2 (PBS-pH8), and then incubated for 10 min at 48C with
freshly prepared EZ-LinkTM NHS-SS-biotin at 3 mg/ml
(Perbio Science) in PBS-pH8. Biotinylation was terminated by
washing the dishes twice with PBS containing 1% BSA (quench-
ing any unbound NHS-SS-biotin) followed by a 10 min incuba-
tion. After incubation, cells were washed with PBS and then
lysed with 1 ml of PBS (with 1% Triton X100 and 1x EDTA-free
protease inhibitor cocktail). Avidin-agarose beads (Pierce
Protein Research Products, Rockford, IL, USA) were added to
900 ml of lysate, and rotated overnight at 48C. The remaining
100 ml was used for total protein assessment. The biotin–
avidin agarose complexes were then harvested by centrifugation
and washed three times with lysis buffer. The beads were then
resuspended in 5× sample loading buffer and boiled for 5 min
prior to SDS–PAGE.
Immunofluorescence
MRC5-BMPR-II-GFP cells were seeded onto BD FalconTM
glass chamber slides (BD Biosciences) and cultured for 48 h
prior to treatment. After treatment, the chamber slides were
washed with PBS and fixed and permeabilized with 1:1 acetone:-
methanol. Prior to staining cells were blocked with 10% FBS in
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PBS. LAMP-1 was detected with the primary antibody mouse
anti-human-LAMP-1 at 1:200 (Dako, Ely, UK) and a secondary
rabbit anti-mouse TRITC (Dako) antibody at 1:500. Chamber-
slides were washed three times with PBS and mounted in gly-
cerol/PBS solution DAPI (Vectashield, Peterborough, UK).
Cells were viewed and photographed using a confocal micro-
scope (Leica TCS SPE) and images captured using Leica LAS
AF software.
Statistical analysis
Statistical analysis was performed using Student’s t-test (∗P ,
0.05, ∗∗P, 0.01 and ∗∗∗P, 0.001).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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